Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:IVA NASDAQ:MNPR NASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.22-3.4%$5.03$2.25▼$6.75$596.75M2.211.59 million shs1.76 million shsIVAInventiva$4.55-17.7%$5.13$1.68▼$6.55$435.26M0.6682,792 shs338,026 shsMNPRMonopar Therapeutics$87.82-13.0%$54.12$4.50▼$105.00$541.85M1.4284,757 shs161,755 shsPYXSPyxis Oncology$3.70-3.5%$1.78$0.83▼$5.39$229.47M1.33819,014 shs1.99 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-3.42%-3.27%+23.17%+69.48%+3.15%IVAInventiva-17.72%-30.32%-17.72%+35.82%+169.23%MNPRMonopar Therapeutics-13.02%-11.64%+104.71%+138.19%+1,628.74%PYXSPyxis Oncology-3.52%+43.77%+97.59%+218.53%+17.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.22-3.4%$5.03$2.25▼$6.75$596.75M2.211.59 million shs1.76 million shsIVAInventiva$4.55-17.7%$5.13$1.68▼$6.55$435.26M0.6682,792 shs338,026 shsMNPRMonopar Therapeutics$87.82-13.0%$54.12$4.50▼$105.00$541.85M1.4284,757 shs161,755 shsPYXSPyxis Oncology$3.70-3.5%$1.78$0.83▼$5.39$229.47M1.33819,014 shs1.99 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-3.42%-3.27%+23.17%+69.48%+3.15%IVAInventiva-17.72%-30.32%-17.72%+35.82%+169.23%MNPRMonopar Therapeutics-13.02%-11.64%+104.71%+138.19%+1,628.74%PYXSPyxis Oncology-3.52%+43.77%+97.59%+218.53%+17.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.63Moderate Buy$16.29161.83% UpsideIVAInventiva 2.63Moderate Buy$16.14254.79% UpsideMNPRMonopar Therapeutics 3.00Buy$103.2517.57% UpsidePYXSPyxis Oncology 2.43Hold$7.75109.74% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, IVA, CMPS, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/9/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.0010/8/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IVAInventivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PYXSPyxis OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.009/30/2025IVAInventivaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/29/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$70.00 ➝ $105.009/27/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AIVAInventiva$9.95M43.74N/AN/A($1.21) per share-3.76MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/APYXSPyxis Oncology$16.15M14.19N/AN/A$2.03 per share1.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)Latest PYXS, IVA, CMPS, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/14/2025Q2 2025PYXSPyxis Oncology-$0.36-$0.30+$0.06-$0.30N/A$2.82 million8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82IVAInventivaN/A2.96N/AMNPRMonopar TherapeuticsN/A33.9333.93PYXSPyxis OncologyN/A5.655.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%IVAInventiva19.06%MNPRMonopar Therapeutics1.83%PYXSPyxis Oncology39.09%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%IVAInventiva32.00%MNPRMonopar Therapeutics20.50%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionablePYXSPyxis Oncology6062.02 million55.44 millionOptionablePYXS, IVA, CMPS, and MNPR HeadlinesRecent News About These CompaniesPyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss RatingsOctober 10 at 6:21 AM | marketbeat.comPyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital MarketsOctober 9 at 7:51 AM | quiverquant.comQPyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital MarketsOctober 9 at 7:30 AM | globenewswire.comPyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell"October 4, 2025 | americanbankingnews.comPyxis Oncology (NASDAQ:PYXS) Downgraded to Sell Rating by Wall Street ZenOctober 3, 2025 | marketbeat.comPyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutionsOctober 2, 2025 | finance.yahoo.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 24, 2025 | marketbeat.comShould You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?September 15, 2025 | zacks.comPyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)September 12, 2025 | seekingalpha.comInvesting in Oncology: 3 Cancer Stocks With Promising PipelinesSeptember 8, 2025 | zacks.comGuggenheim Initiates Coverage of Pyxis Oncology (PYXS) with Buy RecommendationSeptember 5, 2025 | msn.comPyxis Oncology initiated with a Buy at GuggenheimSeptember 3, 2025 | msn.comPyxis Oncology to Participate in September Investor and Industry ConferencesAugust 21, 2025 | globenewswire.comPyxis Oncology reports Q2 EPS (30c), consensus (35c)August 14, 2025 | msn.comPyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comWe Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth CarefullyAugust 2, 2025 | finance.yahoo.comPyxis Oncology Inc News (PYXS) - Investing.comJuly 8, 2025 | investing.comPyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXSJuly 3, 2025 | marketwatch.comPyxis Oncology Appoints New Principal Financial OfficerJuly 3, 2025 | tipranks.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming SectorBy Nathan Reiff | October 7, 2025Broadcom’s VMware Push Takes Aim at Microsoft, Google, & AmazonBy Leo Miller | October 6, 2025Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s MoveBy Chris Markoch | October 9, 2025Behind D-Wave's Massive Week (And Why Rivals Also Popped)By Nathan Reiff | October 6, 2025PYXS, IVA, CMPS, and MNPR Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$6.22 -0.22 (-3.42%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$6.16 -0.06 (-1.05%) As of 10/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Inventiva NASDAQ:IVA$4.55 -0.98 (-17.72%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.89 +0.34 (+7.47%) As of 10/10/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Monopar Therapeutics NASDAQ:MNPR$87.82 -13.14 (-13.02%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$87.50 -0.31 (-0.36%) As of 10/10/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Pyxis Oncology NASDAQ:PYXS$3.70 -0.14 (-3.52%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$3.68 -0.01 (-0.27%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
